KYNA) is a product of the normal metabolism of amino acid L-tryptophan. It has been shown that kynurenic acid possesses neuroactive activity. It acts as an antiexcitotoxic and anticonvulsant, most likely through acting as an antagonist at excitatory amino acid receptors. Because of this activity, it may influence important neurophysiologic and neuropathologic processes. As a result, kynurenic acid has been considered for use in therapy in certain neurobiological disorders. Conversely, increased levels of kynurenic acid have also been linked to certain pathological conditions.
Kynurenic acid was discovered in 1853 by the German chemist Justus von Liebig in dog urine. It is formed from L-kynurenine in a reaction catalyzed by the enzyme kynurenine—oxoglutarate transaminase.
Organism species: Pan-species (General)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | CPD718Ge11 | BSA Conjugated Kynurenic Acid (KYNA) | Immunogen; SDS-PAGE; WB. |
CPD718Ge21 | OVA Conjugated Kynurenic Acid (KYNA) | Immunogen; SDS-PAGE; WB. | |
Antibodies | PAD718Ge01 | Polyclonal Antibody to Kynurenic Acid (KYNA) | ELISA, CLIA. / IHC-Fr, ICC, IP (predicted). |
Assay Kits | CED718Ge | ELISA Kit for Kynurenic Acid (KYNA) | Enzyme-linked immunosorbent assay for Antigen Detection. |